CLINICAL TRIALS PROFILE FOR PENTOSAN POLYSULFATE SODIUM

All Clinical Trials for PENTOSAN POLYSULFATE SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003825 ↗	Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	RATIONALE: Pentosan polysulfate may be effective in treating side effects of radiation therapy to the abdomen or pelvis. It is not yet known whether pentosan polysulfate is more effective than no further therapy for treating gastrointestinal disturbance caused by previous radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of pentosan polysulfate in treating patients who have inflammation of the rectum, diarrhea, or blood in stools caused by previous radiation therapy to the abdomen and pelvis.
NCT00003825 ↗	Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy	Completed	Radiation Therapy Oncology Group	Phase 3	1999-06-01	RATIONALE: Pentosan polysulfate may be effective in treating side effects of radiation therapy to the abdomen or pelvis. It is not yet known whether pentosan polysulfate is more effective than no further therapy for treating gastrointestinal disturbance caused by previous radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of pentosan polysulfate in treating patients who have inflammation of the rectum, diarrhea, or blood in stools caused by previous radiation therapy to the abdomen and pelvis.
NCT00086684 ↗	Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis	Terminated	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 4	2003-09-01	The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain or discomfort associated with interstitial cystitis.

Clinical Trial Conditions for PENTOSAN POLYSULFATE SODIUM

Condition Name

Condition Name for PENTOSAN POLYSULFATE SODIUM
Intervention	Trials
Osteoarthritis, Knee	3
Interstitial Cystitis	2
Bipolar Disorder	1

Condition MeSH

Condition MeSH for PENTOSAN POLYSULFATE SODIUM
Intervention	Trials
Osteoarthritis, Knee	3
Osteoarthritis	3
Cystitis	3

Clinical Trial Locations for PENTOSAN POLYSULFATE SODIUM

Trials by Country

Trials by Country for PENTOSAN POLYSULFATE SODIUM
Location	Trials
United States	77
Canada	13
Australia	3
Brazil	1

Trials by US State

Trials by US State for PENTOSAN POLYSULFATE SODIUM
Location	Trials
Illinois	4
New York	3
Florida	3
Texas	3
North Carolina	2

Clinical Trial Progress for PENTOSAN POLYSULFATE SODIUM

Clinical Trial Phase

Clinical Trial Phase for PENTOSAN POLYSULFATE SODIUM
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	2
Phase 3	2

Clinical Trial Status

Clinical Trial Status for PENTOSAN POLYSULFATE SODIUM
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	3
RECRUITING	1

Clinical Trial Sponsors for PENTOSAN POLYSULFATE SODIUM

Sponsor Name

Sponsor Name for PENTOSAN POLYSULFATE SODIUM
Sponsor	Trials
Paradigm Biopharmaceuticals USA (INC)	2
Radiation Therapy Oncology Group	1
Paradigm Biopharmaceuticals Ltd.	1

Sponsor Type

Sponsor Type for PENTOSAN POLYSULFATE SODIUM
Sponsor	Trials
Other	7
Industry	6
NIH	1

Clinical Trials, Market Analysis, and Projections for Pentosan Polysulfate Sodium

Last updated: February 24, 2026

What is the current status of clinical trials for Pentosan Polysulfate Sodium?

Pentosan Polysulfate Sodium (PPS) is an oral medication originally approved in 1978 for interstitial cystitis (IC) in the United States. Recent interest centers on its potential for other indications, including osteoarthritis and COVID-19-related complications.

Clinical Trials Overview

As of 2023, over 20 clinical trials are registered globally, with key studies summarized below:

• Osteoarthritis (OA): Multiple trials investigate PPS's efficacy in knee OA. Notable is NCT03552333, a phase 2 trial with 120 participants, completed in 2021. Results indicate moderate symptom relief but inconclusive structural benefits.
• COVID-19: NCT04694952, a phase 2 trial, evaluates PPS for COVID-19-related coagulopathy, recruiting 80 participants, ongoing as of late 2022.
• Interstitial Cystitis: Several trials, including NCT01929665, evaluate long-term safety and effectiveness, with mixed results reported.

Regulatory Status Updates

In the U.S., PPS remains FDA-approved solely for IC. European authorities maintain similar indications. No recent approvals for new indications have been granted; ongoing trials aim to expand its label.

What is the market size and competitive landscape?

Current Market Metrics

• Global PPS Market: Estimated at $200 million in 2022, primarily driven by IC treatment.
• Revenue Breakdown: North America accounts for 60%, Europe 25%, Asia-Pacific 10%, rest of the world 5%.
• Pricing: Approximate annual cost per patient ranges from $1,500 to $3,000, depending on dosage.

Market Drivers and Limitations

• Drivers:
  • Established use in IC despite limited expansion.
  • Emerging evidence for OA and other indications.
  • Favorably positioned as an oral alternative to invasive therapies.
• Limitations:
  • Limited brand recognition outside IC.
  • Variable clinical trial outcomes.
  • Regulatory hurdles for new indications.

Competitive Landscape

• Key Competitors: D-mannose-based therapies, corticosteroid injections, and emerging biologics.
• Differentiators:
  • Oral administration.
  • Established safety profile.
  • Long-term manufacturing presence.

What are market projections for PPS over the next decade?

Growth Forecasts

Year	Estimated Market Size	Compound Annual Growth Rate (CAGR)
2023	$200 million	—
2025	$240 million	10%
2030	$350 million	12%

Projections assume successful expansion into OA and anti-thrombotic applications, combined with ongoing clinical validation.

Key Factors Influencing Growth

• Positive trial outcomes for OA could double the current market size within five years.
• Regulatory approvals for new indications could generate significant sales increases.
• Competition from emerging therapies may cap growth potential.

Summary of strategic considerations

• Ongoing trials in OA and coagulopathy could change PPS’s market dynamics.
• The drug’s established safety profile facilitates regulatory efforts.
• Building partnerships with biotech firms focused on musculoskeletal and cardiovascular indications can accelerate growth.

Key Takeaways

• Clinical research on PPS extends beyond its traditional use, focusing on OA and COVID-19-related conditions.
• The global PPS market was $200 million in 2022, with potential for substantial growth contingent on successful trial outcomes.
• Market expansion depends on demonstrating efficacy in new indications and gaining regulatory approval.

FAQs

1. What are the main therapeutic applications of Pentosan Polysulfate Sodium?
Primarily used for interstitial cystitis; research explores osteoarthritis, thrombosis, and COVID-19 complications.

2. Are there any recent regulatory approvals for new indications?
No recent approvals beyond IC, but ongoing clinical trials may influence future labeling.

3. How does PPS compare to alternative treatments for osteoarthritis?
It offers an oral route with a favorable safety profile; efficacy results are mixed, with some studies showing symptom relief.

4. What are the risks associated with PPS use?
Risks include bleeding, based on its anticoagulant properties; contraindicated in active bleeding or platelet disorders.

5. What factors could drive PPS market growth in the next five years?
Successful trial outcomes in OA and COVID-19 coagulopathy, regulatory approvals, and increased clinician adoption.

---

References

[1] U.S. Food and Drug Administration. (2022). Pentosan Polysulfate Sodium. Retrieved from https://www.fda.gov

[2] ClinicalTrials.gov. (2023). Search results for Pentosan Polysulfate Sodium. Retrieved from https://clinicaltrials.gov

[3] MarketWatch. (2022). Pentosan Polysulfate Sodium Market Size, Share & Trends. Retrieved from https://www.marketwatch.com

[4] European Medicines Agency. (2022). Summary of Product Characteristics for Elmiron. Retrieved from https://www.ema.europa.eu